RxDoctor Payments Data

Kyle Michaelis, MD

Cardiovascular Disease · Travis Afb, CANPI 1861486425

Payments from drug & device makers

$20,702in general payments, 2019–2025

Across 592 payments — averaging $34.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$14K
  • Impulse Dynamics (USA) Inc.$1K
  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$808
  • Johnson & Johnson$681
  • Amgen$606
  • plus $3K from 27 others

What the payments were for

  • Travel & lodging$1,7278%
  • Food & beverage$18,28988%
  • Education$4592%
  • Gifts$2271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,702 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,024,294
Medicare patients
1,246
Services billed
11,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban303$363,871
EntrestoSacubitril/Valsartan161$245,808
XareltoRivaroxaban101$128,611
FarxigaDapagliflozin Propanediol38$46,983
Repatha SureclickEvolocumab31$41,720
Praluent PenAlirocumab41$37,103
MultaqDronedarone Hcl26$32,984
JardianceEmpagliflozin21$28,129
EdarbyclorAzilsartan Med/Chlorthalidone54$24,233
EdarbiAzilsartan Medoxomil28$17,683
Metoprolol Succinate310$4,458
Nitroglycerin102$2,643
Digoxin70$2,437
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$2,254
Carvedilol244$2,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$220$363,871303 claims
NovartisEntresto$1,064$245,808161 claims
Johnson & JohnsonXarelto$681$128,611101 claims
AstraZenecaFarxiga$29$46,98338 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$68$41,91682 claims
Sanofi-aventis U.S. LLCMultaq$360$32,98426 claims
Boehringer IngelheimJardiance$31$28,12921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Travis Afb

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →